|
|
|
Presented by Trade Commission of Spain
Spain Biotech: An Engine for Economic Change
 Discover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.
Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.
Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.
Access the podcast
|
Medidata Solutions
“What Will Drive Tomorrow’s Health Business Innovation: Technology, Standards or New Business Models?”
 This podcast will discuss the current state of health business innovation, particularly around providing solutions for clinical trials and drug development. Executives from Medidata and SAS will address the following questions:
- Does the health industry need more technology to drive business innovation?
- How does the current state of industry standards impact the ability of technology to drive business innovation?
- Is the lack of integration, inability to enter clean data or data privacy issues posing barriers to fully exploiting today’s technology?
- Are standards and technology adoption hindered by misaligned business models?
Speakers: Glen de Vries, President of Medidata Solutions, and Jason Burke, Global Director of Health and Life Sciences Market Segments, SAS.
Download Now
|
Medidata Solutions
Rising Clinical Trial Delays and Costs - Addressing the Cause, Not the Symptoms
 Protocol complexity is taking a toll on clinical study speed and efficiency: increasingly complicated and ambitious protocols are not only burdening sites and study volunteers but are also prolonging trials and increasing expenses. In response, sponsors have turned to global study placement, restructured site relationships and new site management practices, but the problem remains.
This podcast will discuss:
- Why these responses address only the symptoms, not the underlying cause, of rising clinical trial delays and costs.
- Results of a recent joint Tufts University / Medidata Solutions study.
- New metrics benchmarking protocol design trends.
- Systematic protocol design improvements and why they are essential to clinical trial performance excellence.
Speakers: Ken Getz, Senior Research Fellow at the Tufts Center for the Study of Drug Development, and Ed Seguine, General Manager, Trial Planning Solutions at Medidata.
Download Now
|
Genologics
Next Generation Sequencing  Learn how labs can maximize the value they receive from their next generation sequencing instruments:
- How can labs generate value from their next generation sequencing instruments
- What are the data management challenges for labs conducting next generation sequencing
- What do genomics labs need to look for when evaluating lab and data management systems
- How are different labs using a lab and data management system to address their data management challenges
Download Now
|
Genologics
Manage Your Biorepositories  Learn about solutions for managing your biospecimens and biorepositories:
- What is the single largest challenge facing organizations in terms of accelerating research
- How is data collection being managed across disparate organizations and sites
- How will data be managed in terms of complying with regulations such as HIPAA
- How does solving biorepository data management help organizations that are conducting translational research
- What are examples of how some organizations are tackling this research challenge
Download Now
|
Emerging IT Trends for 2008
Bio-IT World Contributing Editor Salvatore Salamone discusses the major IT trends that potentially will have the greatest impact on drug discovery research in 2008.Listen to the Podcast
|
Emerging IT Trends for 2006
Bio-IT World senior IT editor Sal Salamone discusses the major IT trends that potentially will have the greatest impact on drug discovery research in 2006. (3.59 min)
Jan. 11, 2006 Play the podcast. View list of all Bio-IT World podcasts.
|
Matthew Shanahan, chief marketing officer at Teranode responsible for product direction, talks about the Semantic Web for the life sciences. (9:49)
Interviewed by Salvatore Salamone, senior IT editor, Bio-IT World - Dec. 14, 2005
Play the podcast.
View list of all Bio-IT World podcasts.
|
Turning Genomics Data into Practical Insight With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can: - Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines.
- Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image).
Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands.
New Complimentary Market Survey… Collaborations and Communications Within Drug Discovery Research This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns. An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 Meeting Today’s Challenges in Clinical Trial Supply Management
Sponsored by: Medidata Solutions Worldwide
Setting up and managing the clinical trial involves many complex procedures. Among the most challenging are planning and executing the logistics of the trial’s clinical supplies. This podcast focuses in depth on the following topics which trace current practices and future evolution of this crucial aspect of clinical trials:
- Current practices in clinical trial logistics
- Comparing advances in clinical supply practices to other aspects of clinical trials
- Where current practices fall short of meeting the challenges
- Trends and evolving improvements that may change the way logistics are conducted
Listen Now
More Podcasts
Scientific Software Engineer
Boston MA
$70,000 to $95,000
Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET.
Apply at http://jobs.tessella.com
Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes. As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers. This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions. It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply
Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules. It is therefore suitable for use in a variety of markets including scientific research and clinical applications. As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team. The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market. This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company. Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial leadership, who wish to apply a fresh approach to existing markets. Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries. We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products. Click to Apply
|
|
|